The company will present data from Cohort 1 of its ongoing Phase 2/3 clinical trial of INOpulse in San Antonio, Texas. Bellerophon Therapeutics ...
News
- Bellerophon Presents Data of Ongoing Phase 2/3 Study of INOpulse
- Analysts See $-0.18 EPS for Celcuity Inc. (CELC)
... 2019, also Bizjournals.com with their article: “Biotech startup Celcuity raises $23M in IPO – Minneapolis / St. Paul ... San Antonio Breast Cancer Symposium Evaluating HER2-Negative Breast Cancer Tumors with Hyperactive and ...
- Moderna: 3Q Earnings Snapshot
The biotechnology company posted revenue of $17 million in the period, which also topped Street forecasts. Four analysts surveyed by Zacks ...
- Puma Biotechnology Inc (PBYI) Q3 2019 Earnings Call Transcript
An update on this data including more patients in the neratinib plus for fulvestrant plus trastuzumab arm will be presented at the San Antonio Breast ...
- 3 New Orleans biotech firms announce expansion, jobs
NEW ORLEANS (AP) — New Orleans Mayor LaToya Cantrell and Gov. John Bel Edwards say three New Orleans biotech start-ups are expanding and ...